Expand all sections

Tralokinumab

Extended indication Severe asthma in adults and adolescents inadequately controlled on ICS + LABA.
Therapeutic value No judgement
Registration phase Withdrawn

Product

Active substance Tralokinumab
Domain Lung diseases
Main indication Asthma
Extended indication Severe asthma in adults and adolescents inadequately controlled on ICS + LABA.
Manufacturer AstraZeneca
Budgetting framework Intermural (MSZ)

Registration

Particularity New medicine
Registration phase Withdrawn
Additional remarks Ontwikkeling voor deze indicatie is stopgezet door AstraZeneca (feb 2018).

Therapeutic value

Therapeutic value No judgement

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.